Voyager Therapeutics shares jump after $1.2 billion deal with Novartis
Voyager Therapeutics said on Tuesday Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates. Voyager, whose shares jumped 35% in premarket trading, would provide Novartis a target-exclusive license to access its RNA-based screening platform and…#voyagertherapeutics #voyager #novartis #rna #huntington (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2024 Category: Consumer Health News Source Type: news
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25%
Novartis expanded its gene therapy collaboration with Voyager on Monday, and VYGR stock rocketed above its 200-day line. The post Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign appeared first on Investor's Business Daily.#voyager #vygr (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2024 Category: Consumer Health News Source Type: news
Curiosity and Compassion Fuel Rare Disease Research
Lauren Drouin shares how personal connections and scientific curiosities drive her work on gene therapy viral vectors. (Source: The Scientist)
Source: The Scientist - January 1, 2024 Category: Science Tags: Magazine Issue Source Type: news
Another CRISPR approval not likely'any time soon' - report (NASDAQ:CRSP)
Following the recent FDA green light for the gene therapy Casgevy, "it is unlikely" that approval of a similar product will take place "any time soon," according to a report by GlobalData. According to GlobalData, only 24 CRISPR-based drugs are in Phase 2 trials, with 88% of such drugs in…#fda #globaldata #crispr #vrtx #jaspermorley #crisprtherapeutics #phase2 #aphase3 #crsp #ctx110 (Source: Reuters: Health)
Source: Reuters: Health - December 30, 2023 Category: Consumer Health News Source Type: news
Gene Therapy for Hemophilia Becomes a Reality
(MedPage Today) -- Earlier this year we reported on FDA's approval of valoctocogene roxaparvovec (Roctavian) for adults with severe hemophilia A. In this story, we provide an update on what has happened since.
Two gene therapies have now been... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 29, 2023 Category: Hematology Source Type: news
Another CAR-T Warning; 'Sweet' Cancer Test; 'Molecular Jackhammer' Blows Up Cancer
(MedPage Today) -- Amid an ongoing investigation of CAR T-cell therapy safety, the FDA has added risk of secondary malignancies to the boxed warning for ciltacabtagene autoleucel (Carvykti). (Fierce Pharma)
Cellular and gene therapy will likely... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 28, 2023 Category: Hematology Source Type: news
Felix Munkonge obituary
My father, Felix Munkonge, who has died aged 64 after a stroke, was a biochemist recognised for the key role he played in coordinating the clinical testing of gene therapy as a potential treatment for cystic fibrosis. He was also a contributor to the team at AstraZeneca that supported the manufacturing capability of the Covid-19 vaccine.Felix joined AstraZeneca as a project manager in November 2020, at the height of the pandemic, and was responsible for managing laboratory-scale collaborations with several chief medical officers around the world. That work made a significant contribution to ensuring the global availability...
Source: Guardian Unlimited Science - December 27, 2023 Category: Science Authors: Mandalena Munkonge Tags: Medical research People in science Zambia Cystic fibrosis AstraZeneca King's College London University of Southampton Biology Source Type: news
FDA approves topical treatment for junctional, dystrophic EB FDA approves topical treatment for junctional, dystrophic EB
This is the first approved treatment for wounds associated with JEB and the second for patients with DEB, following the approval of a topical gene therapy in May 2023.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 26, 2023 Category: Dermatology Tags: Dermatology Source Type: news
If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today
It has been just over two years since Bluebird Bio (NASDAQ: BLUE) split into two separate companies. One focused on gene therapies and retained the Bluebird name; another focused on oncology, and now goes under the name 2seventy Bio. Below, I'll look at what your returns would look like if you…#bluebird #fda #lyfgenia #bluebirdbio #davidjagielski #motleyfool (Source: Reuters: Health)
Source: Reuters: Health - December 25, 2023 Category: Consumer Health News Source Type: news
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an example of just that. The market for gene therapy is worth a relatively modest $8.7 billion this year,…#grandviewresearch #crisprtherapeutics #fda #crispr #vertex #pdufa #davidjagielski #motleyfool (Source: Reuters: Health)
Source: Reuters: Health - December 23, 2023 Category: Consumer Health News Source Type: news
Ocugen Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy
MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) OCGN, a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company received alignment from FDA on key aspects of the…#malvern #ocugeninc #ocugen #fda #rho #retinitispigmentosa #shankarmusunuri #cofounderof #phase12 #rp (Source: Reuters: Health)
Source: Reuters: Health - December 21, 2023 Category: Consumer Health News Source Type: news
Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Here ’s Why
Two weeks ago, bluebird bio secured Food and Drug Administration approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in the U.S. who suffer from the condition. (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2023 Category: Consumer Health News Source Type: news
Casgevy and Lyfgenia: Two gene therapies approved for sickle cell disease
Yale doctors discuss the implications of these treatments recently approved by the FDA for those with the debilitating blood disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - December 20, 2023 Category: Universities & Medical Training Source Type: news
Struggling bluebird aims to raise funds through stock sale, unusual financing deal
Typically, a new drug approval — and the third in just two years' time — is good news for a biopharmaceutical company. Not so for bluebird bio Inc., whose new sickle-cell gene therapy is not going quite according to plan. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 19, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
Cryopreservation Best Practices for Cell & amp; Gene Therapy Source Material, Upcoming Webinar Hosted by Xtalks
This free webinar explains cryopreservation in the context of cell therapy development and manufacturing. Attendees will learn the key considerations in the cryopreservation of different biomaterials. The featured speakers will share data related to cell viability with cryopreservation... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 19, 2023 Category: Pharmaceuticals Source Type: news
